Financial Comparison: Pacific Health Care Organization (OTCMKTS:PFHO) vs. IceCure Medical (NASDAQ:ICCM)

Pacific Health Care Organization (OTCMKTS:PFHO) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Pacific Health Care Organization and IceCure Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Health Care Organization	0	0	0	0	0.00
IceCure Medical	1	1	3	0	2.40

IceCure Medical has a consensus target price of $62.70, suggesting a potential upside of 1,617.81%. Given IceCure Medical’s stronger consensus rating and higher possible upside, analysts plainly believe IceCure Medical is more favorable than Pacific Health Care Organization.

Volatility and Risk

Pacific Health Care Organization has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares Pacific Health Care Organization and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pacific Health Care Organization	20.16%	9.95%	9.58%
IceCure Medical	-441.60%	-211.73%	-119.13%

Valuation and Earnings

This table compares Pacific Health Care Organization and IceCure Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Health Care Organization	$6.72 million	1.64	$1.39 million	$0.11	7.82
IceCure Medical	$3.38 million	3.70	-$15.06 million	($7.21)	-0.51

Pacific Health Care Organization has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Pacific Health Care Organization, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.6% of IceCure Medical shares are owned by institutional investors. 61.6% of Pacific Health Care Organization shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Pacific Health Care Organization beats IceCure Medical on 8 of the 14 factors compared between the two stocks.

About Pacific Health Care Organization

Pacific Health Care Organization, Inc., together with its subsidiaries, operates as a specialty workers' compensation cost containment company in the United States. It is involved in managing and administering health care organizations (HCOs) and medical provider networks (MPNs). The company also provides claims-related services, including utilization review, medical case management, medical bill review, employee advocate services, workers' compensation carve-outs, expert witness testimony, and Medicare set-aside services. It serves insurers, third party administrators, self-administered employers, municipalities, and other industries. The company was formerly known as Clear Air, Inc. and changed its name to Pacific Health Care Organization, Inc. in January 2001. Pacific Health Care Organization, Inc. was incorporated in 1970 and is based in Irvine, California.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.